Edward Bilsky

Dr. Edward Bilsky currently serves as the Vice President for Research and Scholarship at the University of New England. He received his B.S. (physics) in 1989 and M.S. (Behavioral Neuroscience) in 1991 from Rensselaer Polytechnic Institute. He went on to earn a Ph.D. in Pharmacology and Toxicology from the University of Arizona Colleges of Medicine and Pharmacy in 1996. After completing a post-doctoral fellowship at the University of Arizona, he became an Assistant Professor at the University of Northern Colorado in 1997. He received that institutions highest honor, the Faculty Member of the Year in the spring of 2001, for his outstanding teaching, research and service to students. In the fall of 2001, he joined the faculty at the University of New England where he is currently a tenured Professor of Pharmacology and serves as the Director of the Center of Excellence in Neuroscience. He lectures on a variety of topics to students in the colleges of Osteopathic Medicine, Health Professions, Arts and Sciences and Pharmacy. Dr. Bilsky's laboratory conducts translational research in the areas of pain, addiction and other neurological disorders. He has received over 5 million dollars in extramural funding through a variety of federal, state and private grants and contracts including the National Institutes of Health, the Office of Naval Research and biotechnology/pharmaceutical companies. He has published over 65 peer-reviewed publications in leading pharmacology journals, and has presented nationally and internationally in a variety of different venues. Dr. Bilsky is a co-founder of a small biotechnology company (Aiko Pharmaceuticals) that is developing a unique class of opioid antagonists for the management of opioid-mediated side effects. He also serves as a consultant for several pharmaceutical companies developing CNS-based therapeutics. He has served as the chair of the University of New England Faculty Assembly and is an Associate Editor for Life Sciences, a journal publishing research in the biomedical sciences. He was recently awarded the 2011 AOA Research Mentor of the Year Award.

Education

B.S.

Rensselaer

1989

M.S.

Rensselaer

1991

Ph.D.

University of Arizona

1996

Clinical Affiliations

Maine

Expertise

General pharmacology

neuroscience

opioid pharmacology

acute and chronic pain

addiction

neuropharmacology.

Research

Current Research

The research in my laboratory is focused on understanding mechanisms associate with chronic pain and addiction, and developing novel treatments for these conditions.

Research Interests

Drug development for neurological disorders including pain and addiction

Mechanisms of opioid receptor regulation in health and disease

Public advocacy for pain awareness and effective pain management

K-12 STEM Education and integration of the liberal arts into science programs

Selected Publications

2014

Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ. In vivo characterization of MMP-2200, a mixed delta/mu opioid agonist, in mice. Journal of Pharmacology and Experimental Therapeutics, 336:767–778, 2011.

Stevenson G, Mercer H, Cormier J, Dunbar C, Benoit L, Adams C, Jezierski J, Luginbuhl A and Bilsky, E.J. Monosodium iodoacetate-induced osteoarthritis produces pain-depressed wheel running in rats: Implications for preclinical behavioral assessment of chronic pain. Pharmacology, Biochemistry and Behavior, 98: 35-42, 2011.

Ezzili C, Mileni M, McGlinchey N, Long JZ, Kinsey SG, Hochstatter DG, Stevens, RC, Lichtman AH, Cravatt BF, Bilsky, EJ, and Boger DL. Reversible Competitive α-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase Containing Additional Conformational Constraints in the Acyl Side Chain: Orally Active, Long Acting Analgesics. Journal of Medicinal Chemistry, 54: 2805-2822, 2011.

Reynolds J, Bilsky EJ and Meng ID. Selective ablation of mu-opioid receptor expressing neurons in the rostral ventromedial medulla attenuates stress-induced mechanical hypersensitivity in rats. Life Sciences, 89: 313-319, 2011.

Yeomans Y, Muthu D, Lowery J, Martinez HN, Abrell L, Lin G, Strom K, Knapp BI, Bidlack JM, Bilsky EJ and Polt R. Phosphorylation of Enkephalins as a Strategy for Increasing CNS Bioavailability. Chemical Biology and Drug Design, 78(5): 749-756, 2011.

Yancey-Wrona J, Dallaire B, Bilsky EJ, Bath B, Burkhart J, Webster L, Magiera D, Yang X, Phelps M and Sadée W. 6β-Naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: An exploratory study. Pain Medicine, 12: 1727-1737, 2011.

Li Y, Lefever MR, Muthu D, Bidlack J, Bilsky EJ and Polt R. Opioid Glycopeptide Analgesics Derived from Endogenous Enkephalins and Endorphins. Future Medicinal Chemistry, 4(2): 205-226, 2012.

Yuan Y, Stevens DL, Braithwaite A, Scoggins KL, Bilsky EJ, Akbarali HI, Dewey WL, Zhang Y. 6β-N-Heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists. Bioorg Med Chem Lett. 22(14):4731-4734, 2012.

Ananthan, S., Saini, S.K., Dersch, C.M., Xu, H., McGlinchey, N., Giuvelis, D., Bilsky, E.J. and Rothman, R.B. 14-Alkoxy- and 14-Acyloxypyridomophinans: Mixed Mu Agonist/Delta Antagonist Opioid Analgesics with Diminished Tolerance and Dependence Side Effects. Journal of Medicinal Chemistry, 55(19):8350-8363, 2012.

Largent-Milnes, T.M., Brookshire, S.W., Hanlon, K.E., Giuvelis, D., Yamamoto, T., Davis, P., Campos, C.R., Moulton, G.W., Nair, P., Deekonda, S., Bilsky, E..J., Hruby, V.J., Porreca, F., Vanderah, T.W.  A Novel Efficacious Antinociceptive Opioid Without Dependence, Rewards, or Emetic Properties in Animals. Journal of Pharmacology and Experimental Therapeutics, 347(1):7-19, 2013.

Podolsky AT, Sandweiss A, Hu, J, Bilsky EJ, Cain JP,  Kumirov VK, Lee YS, Hruby VJ, Vardanyan, RS and Vanderah TW. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Life Sciences, 93:1010-6, 2013.

Li, Y., St. Louis, L., Knapp, B., Muthu, D., Anglin, B., Giuvelis, D. Bidlack, J. Bilsky, E.J. and Polt, R. Amphipathic Helices Influence CNS Antinociceptive Activity of Glycopeptides Related to β-Endorphin. Journal of Medicinal Chemistry, 57(6):2237-46, 2014.

Zhang, Y., Braithwaite, A., Yuan, Y., Streicher, J.M. and Bilsky, E.J. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-30-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand. European Journal of Pharmacology, 736:124-30, 2014.

Other Scholarly Activity

Patents:

1.  Ananthan, S.; Rothman, R. B.; Bilsky, E. J.; Porreca, F. Pyridomorphinans, Pyridazinomorphinans and Use Thereof. U. S. Patent # 7,951,817. Issued May 31st, 2011.

2.  Polt, R.; Bilsky, E. J. Glycosylated Enkephalins. U. S. Patent Application Serial Number 60/449,989. Date of Filing: 02/25/2003.

3.  Polt, R.; Bilsky, E. J. Amphipathic Glycopeptides. U. S. Patent # 7,803,764. Issued September 28th, 2010.

4.  Ananthan, S.; Rothman, R. B.; Bilsky, E. J.; Porreca, F. Pyridomorphinans, Pyridazinomorphinans and Use Thereof. U. S. Patent # 7,541,364. Issued June 2nd, 2009.

5.  Bilsky, E.J. and Sadée, W. Naltrexone Derivatives With Reduced C-6 Position as Neutral Antagonists in the Treatment of Addiction and Related Applications, Provisional Patent. Date of Filing: 10/4/2005.

6.  Sadée, W., Bilsky, E. and Yancey-Wrona, J. Combination Analgesic Employing Opioid Agoist and Neutral Antagonist. U. S. Patent # 8,748,448. Issued June 10th, 2014.

7.  Bilsky, E.J. and Polt, R. Delta-Opioid Receptor Selective Analgesics. US Patent Number 8,575,309 B2. Issued 11/5/2013.

8.  Bilsky, E., Polt, R. and Senderowitz, H. Glucagon-Like Peptide-1 Glycopeptides. US 2013/0281368 A1. U.S. Publication Date 10/24/2013.

Funded Grants

Meng, I. (Principal Investigator),  Interdisciplinary center of excellence for the study of pain and sensory function; Bilsky, E.J. (Co-Investigator and Core-Director),  Total costs: $10,006,381, NIH 1 P20GM103643-01A1, Period of funding: 8/12-5/17

Bilsky, E.J. (Principal Investigator), K-12 STEM Outreach in Neurosciences and Marine Sciences, AAAS STEM Volunteer Program, Total costs: $12,000, Period of funding: 4/14-3/15

Bilsky, E.J. (Principal Investigator), Education and Research Activities Related to Traumatic Brain Injury, Michael T. Goulet Traumatic Brain Injury and Epilepsy Foundation, Total costs: $15,500, Period of funding: 6/13-5/14

Bilsky, E.J. (Principal Investigator), Animal Facilities to Enhance Translational Neuroscience & Pharmacology Research, Maine Technology Asset Fund, Total costs: $1,533,000, MTAF2052, Period of funding: 7/09-6/14

Bilsky, E.J. (Principal Investigator), Improving the Treatment of Cancer Related Pain Program, Maine Cancer Foundation, Total costs: $ 22,540, MCF260084, Period of funding: 6/1/13-5/31/14

Bilsky, E.J. (Principal Investigator), Validation of New Approaches to White Blood Cell Collection in Humans, Abogen LLC., Total costs: $26,600, Period of funding: 4/13-6/14

Bilsky, E.J. (Principal Investigator), Assessing Gel Based Delivery of Drugs for Veterinary Applications, Clear H2O Inc.  Total costs: $53,050, Period of funding: 1/11-7/14

Bilsky, E.J. (Principal Investigator), Assessing Efficacy and Side Effects of Novel Opioid Peptides, Stealth Peptide, Total costs: $ 62,000, Period of funding: 9/12-6/15

Invited Plenary Presentation

2012-2014

  1. World Pharma Congress Annual Meeting: Pain, Novel Drug Targets and Screening Tools, “Are We Making Progress in Developing and Validating Preclinical Animal Models of Pain and Analgesia?”, 2014.
  2. World Pharma Congress Annual Meeting: Pain, Novel Drug Targets and Screening Tools, “Moderate Rountable Discussion on Evaluating and Validating Animal Models of Pain”, 2014.
  3. 13th Annual Northeast Osteopathic Medical Education Network (NEOMEN-OPTI) Spring Educational Meeting, “Lighting the Song With Sense and Color: A Humanistic Approach to Biomedical Research, 2014.
  4. University of California Davis Medical Campus, “Updates on the Physiology and Pharmacology of Pain”, 2014.
  5. Advisory Board, UC Davis Pain Clinic, “Integrating Science and the Humanities into a Comprehensive Approach for the Prevention and Treatment of Chronic Pain”, 2014.
  6. University of California Davis Medical Campus, Pain Residency and Fellowship Program, “Current Controversies in Opioid Pharmacology”, 2014.
  7. Tufts University, School of Medicine Pain Research, Education and Policy lecture series, “Lighting the Song With Sense and Color: An Interprofessional Humanistic Approach to Relieving Pain in America, 2014.
  8. Providers’ Clinical Support System for Opioid Therapies (PCSS-O) webinar, “Opioid Agonists and Antagonists for Pain and Addiction: The Good, The Bad and The Uncertain”., 2014.
  9. Yale University, Department of Pharmacology. “Are We Making Progress in Developing and Validating Preclinical Animal Models of Pain and Analgesia?”. 2014.
  10. Western New England University, Neuroscience Program, “Opioid Neutral Antagonists”. 2014.
  11. UNE TedX talk. “Lighting the Song With Sense and Color: An academic perspective on chronic pain and how we can minimize its impact on individuals and communities”. 2013.
  12. Student National Medical Association 2013 Regional Conference. “Outside Looking In: How Education, Research and Community Activism Can Reduce the Global Pain Burden”. 2013.
  13. 7th Annual Pain Therapeutics Summit West comnference. “New Approaches for Preclinical Assessment of Analgesic Efficacy and Side Effects”. 2013.
  14. UNECOM Premier Primary Care Fall Weekend Update. “New Developments in the Neuroscience of Pain: Implications for Primary Care Medicine”. 2013.
  15. Osteopathic Medical Education (OMED) Annual Conference. “Neurobiology of Chronic Opioid Administration: Implications for Chronic Pain Management and Addiction Medicine”. 2013.
  16. 7th Annual Pain Therapeutics Summit East comnference. New Approaches for Preclinical Assessment of Analgesic Efficacy and Side Effects”. 2013.
  17. World Pharma Congress Annual Meeting: Targeting Pain With Novel Therapeutics. “Dual Targeting μ Agonist/∂ Antagonist Opioid Analgesics”. 2013.
  18. Eli Lilly Inc. “Management of Opioid-Related Side Effects”, Indianapolis, Indiana, 2013.
  19. Interdisciplinary Pain Seminar Series, “Next Generation Opioid Therapeutics: Where are the Opportunities and What is on the Horizon”, University of Pennsylvania, Philadelphia, Pennsylvania, 2013.
  20. National Science Teachers Association Annual Meeting, “Shaken Up: Teaching About Childhood Sports Injuries and the Brain”, San Antonio, Texas, 2013.
  21. Providers’ Clinical Support System for Opioid Therapies (PCSS-O) webinar, “Updates on Opioid Pharmacology: Implications for Research and Clinical Practice”., 2013.
  22. Maine Osteopathic Association Midwinter Symposium, “Tangled up in Blue: The Complexity of Chronic Pain from a Neuroscientist’s Perspective”, Portland, Maine, 2013.
  23. University of California Davis, Pain Medicine Group, Sacramento California, “Opioid Antagonists and the Management of Opioid-Related Side Effects", 2013.
  24. University of California Davis, Pain Medicine Group, Sacramento California, “Tangled Up In Blue: The Complexity of Chronic Pain From a Neuroscientist's Perspective”, 2013.
  25. Maine Cancer Foundation Annual Meeting, Portland Maine “Is Maine the Home of the Next-Gen Research Revolution?” 2012.
  26. Tradeline 24th Annual Conference on College and University Science Facilities. “Phased growth models for biomedical research facilities”, 2012.
  27. 117th Annual Osteopathic Medical Conference & Exposition, AOA Public Health Seminar. “Tangled Up In Blue: How neuroscience research is providing new insights into the treatment of pain, addiction and their co-morbidities”, 2012.
  28. Council on Undergraduate Research Biennial Research Conference-Ewing NJ, “Expanding Undergraduate Research Opportunities Using a Cost Effective Center Model”, 2012.
  29. World Pharma Congress Annual Meeting: Targeting Pain With Novel Therapeutics. “Rethinking Animal Models and Predictivity”. Chairman and Moderator of Morning Session. 2012.
  30. World Pharma Congress Annual Meeting: Targeting Pain With Novel Therapeutics. “Interactive Discussion Group-The Next Generation of Opioid Therapeutics”. 2012.
  31. National Conference on Undergraduate Research-Ogden UT, “Expanding Undergraduate Research Opportunities Using a Cost Effective Center Model”, 2012.
  32. Keynote Address, Interprofessional Education Spring Symposium, “Coordinated Brain Care: How Neuroscience Discoveries and Interprofessional Practices can Improve Patient and Population Health”, 2012.
  33. 26th Annual Neuroscience Day at Dartmouth, “Constitutive Activity of Opioid Receptors: Implications for Treating Pain and Addiction”, 2012.
  34. Togus VA Medical Center, “Opioid Antagonists as Adjunct Medications for Treating Chronic Pain Patients”, 2012.

Edward Bilsky

,

Ph.D.

Vice President for Research and Scholarship; Professor of Pharmacology, Director of the Center for Excellence in the Neurosciences

Eligible for Student Opportunities